Nucleolar protein DCAF13 promotes non–small cell lung cancer cell proliferation via facilitating rDNA transcription and ribosome biogenesis

Xiaomin Wang, Meng‐Dan Lv, Zhongjie Wu, Xiaohui Wu, G G Sun, Zihao Wu, Xin-Kai Zou, Yutao Wu, Lanqin Liu, Limei Yin, Yi Zhang, En‐hui Yang, Yongxia Zheng, Long Xu, Guoxin Hou, Yu Wang, Yaling Zhang, Ziwei Hu, Shengbing Liu, Lei Ao, C. Xu, Michal Heger, Shuqun Cheng, Weiwei PanJournal of Biological Chemistry 2025 · DOI

TL;DR

This study identifies DCAF13, a nucleolar protein, as a key driver of non-small cell lung cancer (NSCLC) proliferation. DCAF13 facilitates the transcription of ribosomal DNA (rDNA) by interacting with TAF1A, a crucial component of the RNA polymerase I preinitiation complex, thereby boosting ribosome biogenesis and supporting the high protein synthesis demands of cancer cells. This discovery highlights DCAF13 as a potential therapeutic target and prognostic indicator for NSCLC.

What Problem Does This Paper Address?

Cancer cells, with their rapid growth and high metabolic demands, require significantly increased protein synthesis. This necessitates an amplified production of ribosomes, the cellular machinery responsible for translation. Ribosome biogenesis is a complex process, with the transcription of ribosomal DNA (rDNA) into pre-45S rRNA being a critical rate-limiting step. While it's known that rDNA transcription is upregulated in non-small cell lung cancer (NSCLC) and contributes to its progression, the precise molecular mechanisms driving this enhancement have remained largely unclear. This paper aims to elucidate these mechanisms by investigating the role of specific proteins involved in ribosome biogenesis in NSCLC.

Methods

The researchers employed a multi-pronged approach to investigate the role of DCAF13 in NSCLC:

  • Quantitative PCR (qPCR): Used to measure the expression levels of pre-45S rRNA and DCAF13 mRNA in tumor tissues and cell lines.
  • RNA Polymerase I Inhibition: Utilized the inhibitor CX-5461 to block rDNA transcription and assess its impact on NSCLC cell proliferation and gene expression.
  • Immunofluorescence Microscopy: Employed to determine the subcellular localization of DCAF13 and visualize the effects of treatments on protein distribution.
  • Western Blotting: Used to assess protein expression levels, including DCAF13, proliferation markers (Ki67, BrdU), apoptosis markers (cleaved caspase-3), DNA damage markers (p-H2AX), and cell cycle regulators (p21, p27, p53).
  • siRNA-mediated Knockdown and Plasmid Transfection: Manipulated DCAF13 expression levels to study its functional consequences on rDNA transcription, ribosome biogenesis, and protein synthesis.
  • Co-immunoprecipitation (Co-IP) and Mass Spectrometry: Investigated protein-protein interactions, specifically to identify DCAF13's binding partners, leading to the discovery of its interaction with TAF1A.
  • Chromatin Immunoprecipitation (ChIP) Assay: Examined the binding of DCAF13 to rDNA promoter regions.
  • CRISPR/Cas9 Gene Editing: Created DCAF13 knockout cell lines to definitively assess its role in NSCLC proliferation, colony formation, and migration.
  • In vivo Xenograft Models: Evaluated the impact of DCAF13 knockout on tumor growth in mice.
  • Cell Cycle Analysis (Flow Cytometry): Assessed the distribution of cells in different phases of the cell cycle following treatment.
  • Polysome Profiling: Analyzed ribosome assembly and translation efficiency.
  • Puromycin Incorporation Assay: Measured global protein synthesis rates.
  • Transwell and Wound Healing Assays: Evaluated cell migration and invasion capabilities.

Datasets

The study utilized human NSCLC tumor tissues and adjacent normal tissues obtained from the Affiliated Hospital of Jiaxing University. Additionally, publicly available datasets from TCGA (The Cancer Genome Atlas) for LUAD (lung adenocarcinoma) and LUSC (lung squamous cell carcinoma) were analyzed to assess DCAF13 expression and its correlation with prognosis and clinical stage.

Key Insights and Ideas

  • DCAF13 as a Nucleolar Driver of NSCLC Proliferation: The study firmly establishes DCAF13's critical role in promoting NSCLC cell growth, not just as a general oncogene, but specifically by orchestrating rDNA transcription.
  • Direct Interaction with TAF1A is Crucial: The discovery that DCAF13 directly interacts with TAF1A, a key component of the RNA polymerase I preinitiation complex, provides a concrete mechanistic link between DCAF13 and rDNA transcription. This interaction appears essential for the proper assembly of this complex.
  • DCAF13 Orchestrates the Entire Ribosome Biogenesis Pathway: Beyond just transcription, DCAF13's influence extends to ribosome biogenesis and global protein synthesis, highlighting its central role in fueling cancer cell growth.
  • DCAF13 as a Prognostic Biomarker: The strong correlation between high DCAF13 expression and poor patient survival in NSCLC positions it as a valuable prognostic indicator.
  • RNA Polymerase I Inhibitors Affect DCAF13: Interestingly, the study observed that rDNA transcription inhibitors like CX-5461 and Act. D also reduced DCAF13 expression, suggesting a complex interplay where inhibiting rDNA transcription might feedback on DCAF13 levels.

Key Results

  • Upregulated pre-45S rRNA in NSCLC: Pre-45S rRNA levels were significantly higher in NSCLC tumor tissues compared to normal tissues.
  • CX-5461 Inhibits NSCLC Growth: Treatment with the RNA polymerase I inhibitor CX-5461 significantly suppressed NSCLC cell proliferation, tumor volume, and tumor weight in vivo.
  • DCAF13 Localizes to the Nucleolus: DCAF13 was found to be predominantly localized within the nucleolus of NSCLC cells.
  • DCAF13 Knockdown Impairs rDNA Transcription and Ribosome Biogenesis: Silencing DCAF13 led to reduced pre-45S rRNA expression, impaired ribosome biogenesis, and decreased global protein synthesis.
  • DCAF13 Interacts with TAF1A: Co-immunoprecipitation experiments confirmed a direct interaction between DCAF13 and TAF1A.
  • DCAF13 is Highly Expressed in NSCLC and Correlates with Poor Prognosis: DCAF13 mRNA and protein levels were elevated in NSCLC tissues, and higher expression was associated with shorter overall survival.
  • DCAF13 Knockout Inhibits NSCLC Cell Proliferation, Colony Formation, and Migration: Genetic deletion of DCAF13 significantly reduced these key cancer cell behaviors.
  • DCAF13 Knockout Suppresses Tumor Growth In Vivo: Tumors formed by DCAF13 knockout cells were smaller and weighed less than those from wild-type cells.

Limitations and Future Work

  • Mechanism of DCAF13 Regulation by rDNA Inhibitors: While the study observed that CX-5461 and Act. D reduced DCAF13 expression, the precise mechanism behind this downregulation was not fully elucidated and warrants further investigation.
  • Role of DCAF13 in Nucleolar Stress: The paper suggests DCAF13 might play a role in nucleolar stress, particularly in response to rDNA transcription inhibition. Further research could explore this connection and its implications for p53 activation.
  • Therapeutic Potential of DCAF13 Inhibition: While DCAF13 is identified as a promising target, further studies are needed to develop and validate specific DCAF13 inhibitors for NSCLC treatment. The paper hints at the potential for combining rDNA transcription inhibitors with other anticancer drugs, which could be explored further in the context of DCAF13 targeting.
  • Broader Cancer Relevance: While the study focuses on NSCLC, the fundamental role of ribosome biogenesis in cancer suggests that DCAF13 might be relevant in other cancer types as well, meriting further investigation.

Summary updated

Abstract

The nucleolus is an important nonmembranous organelle within the nucleus and is responsible for ribosome biogenesis. This process is frequently upregulated in tumors to support elevated protein synthesis and sustain tumor growth. The transcription of ribosomal DNA (rDNA) into pre-45S rRNA, a rate-limiting step in ribosomal biogenesis, has been reported to be enhanced to drive the progression of non-small cell lung cancer (NSCLC). However, the mechanism that upregulating rDNA transcription in NSCLC remains unclear. Here, we show that rDNA transcript levels were increased in NSCLC tumor tissues. Reduction of rDNA transcription by CX-5461, an RNA polymerase I inhibitor, significantly inhibited NSCLC cell proliferation. We found that the expression level of DDB1- and CUL4-associated factor 13 (DCAF13), a nucleolar protein, positively correlated with that of pre-45S rRNA. DCAF13 knockdown impairs rDNA transcription, ribosome biogenesis, and protein synthesis, indicating that DCAF13 participates in rDNA transcription. Mechanistically, DCAF13 interacts directly with TAF1A, a component of the RNA polymerase I preinitiation complex. This interaction is necessary for preinitiation complex assembly. In addition, DCAF13 is highly expressed in NSCLC, and its expression is negatively correlated with the overall survival in NSCLC patients. DCAF13 knockout inhibited NSCLC cell proliferation, colony formation, and migration, indicating that DCAF13 is a poor prognosis indicator of NSCLC. In summary, we found that DCAF13 promotes NSCLC cell proliferation by coordinating with TAF1A to regulate rDNA transcription and maintain high ribosome biogenesis.
BibTeX
@article{wang2025nucleolar,
  author = {Xiaomin Wang and Meng‐Dan Lv and Zhongjie Wu and Xiaohui Wu and G G Sun and Zihao Wu and Xin-Kai Zou and Yutao Wu and Lanqin Liu and Limei Yin and Yi Zhang and En‐hui Yang and Yongxia Zheng and Long Xu and Guoxin Hou and Yu Wang and Yaling Zhang and Ziwei Hu and Shengbing Liu and Lei Ao and C. Xu and Michal Heger and Shuqun Cheng and Weiwei Pan},
  title = {{Nucleolar protein DCAF13 promotes non–small cell lung cancer cell proliferation via facilitating rDNA transcription and ribosome biogenesis}},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  doi = {10.1016/j.jbc.2025.110656},
}
Figure